Evidence map›Paper›PMID 27021515›Full record

ArticleScientific reports2016

miR-93 functions as an oncomiR for the downregulation of PDCD4 in gastric carcinoma.

Hongwei Liang, Feng Wang, Danping Chu, Weijie Zhang, Zhicong Liao, Zheng Fu, Xin Yan, Hao Zhu, Wen Guo, Yujing Zhang and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. MiRNA-93: a novel signature in human disorders and drug resistance.Cell communication and signaling : CCS · 2023
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Non-coding RNAs underlying chemoresistance in gastric cancer.Cellular oncology (Dordrecht, Netherlands) · 2020
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hongwei LiangState Key Laboratory of Pharmaceutical Biotechnology, NJU Advanced Institute for Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Science, Nanjing University, Nanjing, Jiangsu 210093, China.
Feng WangDepartment of General Surgery, The Affiliated Drum Tower Hospital of Medical School of Nanjing University and Nanjing Multi-center Biobank, Nanjing, Jiangsu 210008, China.
Danping ChuState Key Laboratory of Pharmaceutical Biotechnology, NJU Advanced Institute for Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Science, Nanjing University, Nanjing, Jiangsu 210093, China.
Weijie ZhangDepartment of General Surgery, The Affiliated Drum Tower Hospital of Medical School of Nanjing University and Nanjing Multi-center Biobank, Nanjing, Jiangsu 210008, China.
Zhicong LiaoDepartment of Cardio-Thoracic Surgery, The Affiliated Drum Tower Hospital of Medical School of Nanjing University and Nanjing Multi-center Biobank, Nanjing, Jiangsu 210008, China.
Zheng FuState Key Laboratory of Pharmaceutical Biotechnology, NJU Advanced Institute for Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Science, Nanjing University, Nanjing, Jiangsu 210093, China.
Xin YanDepartment of Respiratory Medicine, The Affiliated Drum Tower Hospital of Medical School of Nanjing University and Nanjing Multi-center Biobank, Nanjing, Jiangsu 210008, China.
Hao ZhuDepartment of Gastroenterology, The Affiliated Drum Tower Hospital of Medical School of Nanjing University and Nanjing Multi-center Biobank, Nanjing, Jiangsu 210008, China.
Wen GuoDepartment of Endocrinology, Nanjing Municipal Hospital for Governmental Organizations, Nanjing, Jiangsu 210018, China.
Yujing ZhangState Key Laboratory of Pharmaceutical Biotechnology, NJU Advanced Institute for Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Science, Nanjing University, Nanjing, Jiangsu 210093, China.
Wenxian GuanDepartment of General Surgery, The Affiliated Drum Tower Hospital of Medical School of Nanjing University and Nanjing Multi-center Biobank, Nanjing, Jiangsu 210008, China.
Xi ChenState Key Laboratory of Pharmaceutical Biotechnology, NJU Advanced Institute for Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, School of Life Science, Nanjing University, Nanjing, Jiangsu 210093, China.
Nanjing Drum Tower Hospital · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death 4 (PDCD4), as a tumor suppressor gene, is frequently reduced in a variety of tumors, including gastric cancer. Previous findings have indicated that PDCD4 participates in tumorigenesis through the regulation of apoptosis, but the molecular basis of this process has not been fully elucidated, and no studies have shown the upstream regulation of this gene in gastric cancer. In this study, we used bioinformatics analysis to search for miRNAs that could potentially target PDCD4 and identified miR-93 as a candidate. Moreover, we observed the inverse correlation between miR-93 and PDCD4 protein levels, but not mRNA levels, in human gastric cancer tissues. We further experimentally validated PDCD4 as the direct target of miR-93 by evaluating PDCD4 expression in gastric cancer cells after the overexpression or knockdown of miR-93. Additionally, the biological consequences of targeting PDCD4 through miR-93 were examined using cell apoptosis assays in vitro. We demonstrated that the repression of PDCD4 through miR-93 suppressed the apoptosis of gastric cancer cells. Finally, we revealed that miR-93 promoted the development of gastric tumor growth in xenograft mice by negatively regulating PDCD4. Taken together, the findings of the present study indicated the oncogenic role of miR-93 in gastric cancer tumorigenesis through targeting PDCD4, particularly in apoptosis.

Indexed as

Down-Regulation3' Untranslated RegionsAnimalsApoptosisApoptosis Regulatory ProteinsBlotting, WesternCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMice, SCIDMicroRNAsOncogenesReverse Transcriptase Polymerase Chain ReactionRNA-Binding Proteins3' Untranslated RegionsApoptosis Regulatory ProteinsMicroRNAsMIRN93 microRNA, humanPDCD4 protein, humanRNA-Binding Proteins

Identifiers

PMID27021515
PMCPMC4810498
OpenAlexW2326279830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.